Survey: Compliance Programs Don’t Hurt Bottom Line, But Face Other Hurdles
This article was originally published in The Gray Sheet
Nine out of 10 device and diagnostic firms responding to a survey say implementing a compliance program based on the 1AdvaMed Code of Ethics did not hurt their company's bottom line, including 10% who say their compliance program increased revenue
You may also be interested in...
The House Committee on Oversight and Government Reform is requesting information on the off-label use and marketing of drug-eluting stents
A new survey suggests that medical device firms are complying with industry standards written to prevent fraudulent sales and marketing practices. Roughly 75% of surveyed companies said they post their compliance programs on the company website
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.